| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| November 4, 2025 | ±6.8% | -1.5% | over-priced |
| August 5, 2025 | ±9.2% | +1.8% | over-priced |
| May 6, 2025 | ±3.7% | -1.6% | over-priced |
| November 12, 2024 | ±3.7% | -1.1% | over-priced |
| August 6, 2024 | ±2.8% | +6.6% | under-priced |
| May 2, 2024 | ±1.9% | -8.5% | under-priced |
| November 2, 2023 | ±2.0% | +4.5% | under-priced |
| July 27, 2023 | ±2.6% | -7.1% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q4 FY2025 | $-2.20 | $3.0B | $-1.1B |
| Q3 FY2025 | $-0.09 | $2.8B | $-46M |
| Q2 FY2025 | $0.18 | $2.8B | $91M |
| Q1 FY2025 | $0.25 | $2.6B | $126M |
Baxter International Inc. (BAX) reports imminently, with the next report estimated for May 3, 2026. Across the last 8 reports, options priced an average ±4.1% earnings move while the stock actually moved 4.1% on average — the market has been roughly fair on BAX's earnings risk. Fundamentals into the print: EPS down 914.8% year-over-year, revenue up 10.2%. QuantLogix's live 5-factor engine currently reads BAX as a buy at 58/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →